Leaders with RadNet Inc. recently discussed why they decided to pull the trigger on the company’s blockbuster acquisition of breast artificial intelligence vendor iCAD Inc. The Los Angeles-based imaging center operator first announced the deal Tuesday, with investors receiving 0.0677 shares of RadNet common stock for each share of iCAD held at closing. This represents a transaction value of $103 million or $3.61 per share of iCAD common stock. RadNet believes the acquisition will accelerate its ability to scale AI offerings to meet growing demand, “creating the industry’s most comprehensive portfolio” of breast imaging solutions.
Read the full article: RadNet Leaders Discuss Rationale Behind Blockbuster $103M iCAD AI Acquisition //
Source: https://radiologybusiness.com/topics/healthcare-management/mergers-and-acquisitions/radnet-leaders-discuss-rationale-behind-blockbuster-103m-icad-ai-acquisition